Denmark
# |
Name |
Price to Earnings Ratio (P/E) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
142.31 |
Jan. 14, 2025 | USD 18.73 | 1.26% |
|
Denmark |
|
2 |
62.52 |
Jan. 14, 2025 | USD 70.50 | 0.61% |
|
Denmark |
|
3 |
62.00 |
Jan. 14, 2025 | USD 20.15 | -0.78% |
|
Denmark |
|
4 |
56.18 |
Jan. 14, 2025 | USD 54.16 | -1.39% |
|
Denmark |
|
5 |
32.60 |
Jan. 14, 2025 | USD 109.06 | -0.12% |
|
Denmark |
|
6 |
29.24 |
Jan. 14, 2025 | USD 81.56 | -2.90% |
|
Denmark |
|
7 |
21.39 |
Jan. 14, 2025 | USD 216.88 | 1.28% |
|
Denmark |
|
8 |
15.38 |
Jan. 14, 2025 | USD 5.46 | 0.56% |
|
Denmark |
|
9 |
9.58 |
Jan. 14, 2025 | USD 26.62 | -0.36% |
|
Denmark |
|
10 |
-0.64 |
Jan. 14, 2025 | USD 2.17 | 5.88% |
|
Denmark |
|
11 |
-6.84 |
Jan. 14, 2025 | USD 0.57 | 1.47% |
|
Denmark |
|
12 |
-8.33 |
Jan. 14, 2025 | USD 1.93 | -6.19% |
|
Denmark |
|
13 |
-9.54 |
Jan. 14, 2025 | USD 3.98 | 0.01% |
|
Denmark |
|
14 |
-10.31 |
Jan. 14, 2025 | USD 0.85 | -3.38% |
|
Denmark |
|
15 |
-10.53 |
Jan. 14, 2025 | USD 0.20 | -2.77% |
|
Denmark |
|
16 |
-65.00 |
Jan. 14, 2025 | USD 95.84 | 0.08% |
|
Denmark |
|
17 |
-226.25 |
Jan. 14, 2025 | USD 91.43 | -1.85% |
|
Denmark |
|
18 |
-10,641.44 |
Jan. 14, 2025 | USD 0.64 | 1.38% |
|
Denmark |
The Pharmaceuticals company in Denmark with the highest Price to Earnings Ratio (P/E) is Ambu A/S (Copenhagen Stock Exchange: AMBU-B.CO) at 142.31.
The Pharmaceuticals company in Denmark with the lowest Price to Earnings Ratio (P/E) is Initiator Pharma A/S (Stockholm Stock Exchange: INIT.ST) at -10,641.44.
The top 10 Pharmaceuticals companies in Denmark by Price to Earnings Ratio (P/E) are Ambu A/S, ChemoMetec A/S, ALK-Abelló A/S, Novozymes A/S, Coloplast A/S, Novo Nordisk A/S, Genmab A/S, H. Lundbeck A/S, Bavarian Nordic A/S and ExpreS2ion Biotech Holding AB (publ).
The bottom 10 Pharmaceuticals companies in Denmark by Price to Earnings Ratio (P/E) are Initiator Pharma A/S, Gubra A/S, Zealand Pharma A/S, BioPorto A/S, Q-Interline A/S, FluoGuide A/S, ViroGates A/S, Saniona AB (publ), ExpreS2ion Biotech Holding AB (publ) and Bavarian Nordic A/S.